| Name | Title | Contact Details |
|---|---|---|
Craine Runton |
Director, Security and Compliance | Profile |
We build digital experiences that educate and inform the millions of people who visit our sites.
BrandMaker offers enterprise solutions for your marketing needs. Our software and services can help your company thrive in a competitive landscape. Learn more.
Buy and Sell Domains with DAN.COM. Discover millions of domain names available for sale. DAN.COM keeps you safe.
Retain a sense of security with the Multi Service Fuel Card, one payment method with multiple applications. Give truck drivers save access to fuel and additional funds on the road.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.